Clinical trials: Gastrointestinal Stromal Neoplasms
Gastrointestinal Stromal Tumors
Paclitaxel in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors (GIST) After Failure to Imatinib and Sunitinib
With discovery of KIT mutations and the advent of KIT tyrosine kinase inhibitor imatinib (GlivecTM, Novartis), there has been substantial improvement in overall survival in patients with advanced and/or metastatic…
- Trial name
- NCT02607332
- Testing
- Paclitaxel
- Where
- South Korea
- Volunteers
- 25 people
- Sponsor
- Asan Medical Center
Gastrointestinal Stromal Tumors
Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)
Multicenter, open-label Phase 1b/2 study of ripretinib in combination with binimetinib in patients with gastrointestinal stromal tumor (GIST).
- Trial name
- NCT05080621
- Testing
- Ripretinib, binimetinib
- Sponsor
- Deciphera Pharmaceuticals, LLC
Gastrointestinal Stromal Tumor, Malignant
Correlation Between Imatinib Trough Concentration and Efficacy in Advanced GIST Patients with Different Genotypes
Imatinib (IM) has significantly enhanced the prognosis of patients (pts) with advanced gastrointestinal stromal tumors (GISTs). The clinical outcomes may correlate with IM exposure.
- Trial name
- NCT06628739
- Testing
- Imatinib
- Where
- China
- Volunteers
- 168 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
GIST
Non-Interventional Retrospective Correlation Of Tumor Mutational Status To Clinical Benefit Of GIST Patients Treated With Sunitinib
Retrospective correlation of clinical outcomes data with mutational status in GIST subjects treated with sunitinib.
- Trial name
- NCT01459757
- Testing
- non-interventional
- Where
- 36 sites in United States, Australia and 14 more
- Volunteers
- 322 people
- Sponsor
- Pfizer
Gastro Intestinal Stromal Tumour
Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure
The primary objective is to compare the efficacy of lenvatinib plus Best Supportive Care versus Placebo plus Best Supportive Care in the treatment of patients with advanced GIST, after failure of imatinib and sunitinib.
- Trial name
- LENVAGIST (NCT04193553)
- Testing
- Lenvatinib, Best supportive care
- Where
- 14 sites in France
- Volunteers
- 77 people
- Sponsor
- Centre Leon Berard
Gastrointestinal Stromal Tumors, Germline Mutation
A Retrospective Pharmacokinetics and Pharmacogenomics Research of Imatinib in Gastrointestinal Stromal Tumor Treatment
For patients of GIST (Gastrointestinal Stromal Tumor), Imatinib has been widely used in GIST with KIT or PDGFRA sensitive mutations.
- Conditions
- Gastrointestinal Stromal Tumors, Germline Mutation, Somatic Mutation, Plasma Concentration
- Trial name
- NCT03092128
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Xueding Wang
Gastrointestinal Stromal Tumors
Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib.
This study will evaluate the preliminary efficacy of nilotinib in pretreated patients (Imatinib, Sunitinib) with unresectable or metastatic gastrointestinal stromal tumors.
- Trial name
- NCT01289028
- Testing
- Nilotinib
- Where
- 19 sites in Germany, Italy
- Volunteers
- 125 people
- Sponsor
- Novartis Pharmaceuticals
Pancreatic Ductal Adenocarcinoma
Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma
This is an open-label phase 1/2 study that will combine the chemotherapy agents gemcitabine and nab-paclitaxel with an oral hedgehog inhibitor LDE225 (Sonidegib).
- Trial name
- NCT01431794
- Testing
- LDE225-600mg, Gemcitabine, nab-paclitaxel
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Gastrointestinal Stromal Tumor
Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving imatinib mesylate after surgery may kill any remaining tumor cells.
- Trial name
- NCT00103168
- Testing
- imatinib mesylate
- Where
- 50 sites in Australia, Denmark and 4 more
- Volunteers
- 908 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Advanced Gastrointestinal Stromal Tumors
A Prospective, Multicenter Study on Best Clinical Use of Imatinib in the Advanced Gastrointestinal Stromal Tumors
Open-label, multicenter study of imatinib (400mg/die p.o.)in patients with advanced gastrointestinal stromal tumors. Patients will be treated for up to 12 months.
- Trial name
- NCT00940563
- Testing
- Imatinib
- Where
- 26 sites in Italy
- Volunteers
- 135 people
- Sponsor
- Novartis Pharmaceuticals
GIST, Malignant, Liver Metastases
Comparison of Clinical Efficacy of Liver Resection, RFA, TACE, and Drug Therapy in Patients with GIST LM
The goal of this observational study is to evaluate the overall survival benefits of local treatment combined with imatinib(IM) and IM alone in patients suffering from GIST liver metastases.
- Trial name
- NCT06038552
- Testing
- imatinib (IM), hepatic resection (HR), radiofrequency ablation (RFA)
- Where
- China
- Volunteers
- 238 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Gastrointestinal Stromal Tumors
Current Management of Gastrointestinal Stromal Tumors (GIST) in the Region of Coquimbo
This is a retrospective analysis and description of the preferred diagnostic and treatment methods employed on GIST on the Region of Coquimbo from 2003 to 2008.
- Trial name
- NCT00564265
- Testing
- Observation
- Where
- Chile
- Volunteers
- 24 people
- Sponsor
- Cirujanos la Serena
Pancreatic Cancer, Gastrointestinal Neoplasms
Permission to Collect Blood Over Time for Research
To determine whether biomarkers assessed in blood samples can be used to detect individuals at risk for developing blood clots or worsening of their underlying disease.
- Conditions
- Pancreatic Cancer, Gastrointestinal Neoplasms, Colon Rectal Cancer Adenocarcinoma, Esophageal Cancer
- Trial name
- NCT00767234
- Testing
- Observation
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Stanford University
Gastrointestinal Neoplasm
Kinase Genotyping of Gastro Intestinal Stomach Tumors (GISTs) From Patients Enrolled in Pfizer A6181112 Phase IIIb Trial
The purpose of this study is to determine the genetic makeup of gastro intestinal stomach tumors (GISTs) from patients enrolled in the A6181112 phase IIIb trial.
- Trial name
- NCT00640692
- Sponsor
- Oregon Health and Science University
Metastases, Neoplasm, Colorectal Neoplasms
Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver
MTC-DOX is Doxorubicin or DOX, a chemotherapy drug, that is adsorbed, or made to "stick", to magnetic beads (MTCs). MTCs are tiny, microscopic particles of iron and carbon.
- Conditions
- Metastases, Neoplasm, Colorectal Neoplasms, Esophageal Neoplasms, Stomach Neoplasms
- Trial name
- NCT00041808
- Testing
- MTC-DOX for Injection, Chemotherapy
- Where
- 4 sites in United States, Germany
- Volunteers
- 20 people
- Sponsor
- FeRx
Gastrointestinal Stromal Tumors
Symptom Inventory for Gastrointestinal Stromal Tumors
The goal of this research study is to better understand the symptoms experienced by patients with GIST. There are 3 parts to this study.
- Trial name
- NCT01178307
- Testing
- Questionnaires, Interview, MDASI-GIST Questionnaire
- Where
- United States
- Volunteers
- 187 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Gastrointestinal Neoplasms
A Legacy Study in Participants With Gastrointestinal Stromal Tumors (GIST)
This study aims to evaluate the long-term safety and tolerability of velzatinib (GSK6042981) in adults with GIST who have previously received velzatinib in parent study and continue to benefit from the treatment.
- Trial name
- NCT07843641
- Testing
- Velzatinib
- Volunteers
- 72 people
- Sponsor
- GlaxoSmithKline
Gastrointestinal Stromal Tumors
GIST Oral Paclitaxel(Liporaxel)
The purpose of this study is to evaluate safety and efficacy of Liporaxel for patients with GIST who failed on prior standard treatments, including imatinib, sunitinib, and regorafenib, and with low P-glycoprotein expression.
- Trial name
- NCT06326346
- Testing
- Liporaxel
- Where
- South Korea
- Volunteers
- 28 people
- Sponsor
- Asan Medical Center
Pancreatic Cancer, Lymphadenopathy
Prospective Trial of EUS-FNA Versus EUS-FNB Using a Novel Core Biopsy Needle
Endoscopic ultrasound (EUS) is paramount in the diagnosis and evaluation of cancers involving the gastrointestinal tract. EUS allows for the acquisition of cellular (fine needle aspirate - FNA) or tissue biopsy (fine needle…
- Conditions
- Pancreatic Cancer, Lymphadenopathy, Gastrointestinal Stromal Tumor
- Trial name
- MUCIN (NCT01769248)
- Testing
- Fine needle aspiration, Fine needle biopsy
- Where
- 3 sites in United States
- Volunteers
- 140 people
- Sponsor
- Northwestern University
Gastrointestinal Stromal Tumors, Renal Cell Carcinoma
A Bioequivalence Study of Sunitinib Malate Capsules.
A randomized, open, two-period, two-sequence crossover trial design used to assess the pharmacokinetics and safety of Sunitinib Malate Capsules in healthy volunteers under fed condition, and compare the bioequivalence of…
- Conditions
- Gastrointestinal Stromal Tumors, Renal Cell Carcinoma, Pancreatic Neuroendocrine Tumor
- Trial name
- NCT05800106
- Testing
- Sunitinib malate capsules generic product, Sunitinib malate capsules reference product
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.